Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
AMD 3100 octahydrochloride (HB2739)
Description:Potent, selective CXCR4 antagonist. Mobilizes hematopoietic stem cells.
Anisomycin (HB2239)
Description:Protein synthesis inhibitor. Potent JNK / p38 MAPK activator.
Purity:>98%
Brefeldin A (BFA) (HB2949)
Description:Reversible protein transport inhibitor. Commonly used in cytokine staining. Enhances CRISPR-mediated HDR.
Purity:>98%
Dexamethasone (HB2521)
Description:Anti-inflammatory synthetic glucocorticoid. Induces hMSC differentiation. Apoptosis inducer.
Purity:>98%
Dexamethasone (water-soluble) (HB6020)
Description:Synthetic glucocorticoid with potent anti-inflammatory actions. Induces hMSC differentiation. Apoptosis inducer. Water soluble and suitable for cell culture.Â
Purity:>98%